• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates
Home » FDA probes JNJ, Bard and others on transvaginal mesh risks

FDA probes JNJ, Bard and others on transvaginal mesh risks

January 5, 2012 By Arezu Sarvestani

Transvaginal mesh icon

As public pressure mounts over the potential harm caused by transvaginal mesh implants the FDA ordered device makers, including Johnson & Johnson (NYSE:JNJ) and C.R. Bard (NYSE:BCR), to take another look at complication rates associated with their devices.

The watchdog agency asked a total of 33 companies to conduct 3 years of safety and effectiveness trials under growing concerns after deaths and injuries linked to the products spiked in recent years.

The moves follow citizens’ petitions, multi-district lawsuits and FDA panel meetings surrounding the implants, which were catalyzed by warnings issued in July, that the surgical mesh may pose unnecessary risk to women without adding clinical benefit.

During the Sept. 2010 FDA panel meetings, mesh makers including Johnson & Johnson and Endo Pharmaceuticals Holdings Inc. (NSDQ:ENDP), agreed that more safety studies and labeling changes might help warn patients and doctors of potential risks. The watchdog agency asked Endo to conduct new studies for its vaginal mesh products.

The FDA is now asking manufacturers to collect and review all existing data on the safety and efficacy of the devices, and the agency mandated 88 postmarket surveillance studies between the 33 companies, according to an FDA update.

The watchdog agency added that it’s still considering bumping the mesh from a Class II to a the higher-risk Class III device category, a move that was also discussed in the Sept. meeting.

Late last month 3 U.S. Senators probed Bard on its management of the clamor surrounding its transvaginal mesh devices as part of a larger investigation into medical device recalls, including for Medtronic’s (NYSE:MDT) 2007 Sprint Fidelis recall and Zimmer Holdings (NYSE:ZMH) for its NexGen knee implant.

Read more of MassDevice.com’s coverage of women’s health.

Transvaginal mesh is used to treat pelvic organ prolapse, which occurs when internal support structures become so weak or stretched that organs, like the uterus, bladder or bowels, sag from their normal position and bulge or prolapse into the vagina.

"There are clear risks associated with the transvaginal placement of mesh to treat POP," said Dr. William Maisel, deputy director and chief scientist of the FDA’s Center for Devices & Radiological Health, in an agency release in July. "The FDA is asking surgeons to carefully consider all other treatment options and to make sure that their patients are fully informed of potential complications from surgical mesh. Mesh is a permanent implant – complete removal may not be possible and may not result in complete resolution of complications."

From 2008 to 2010, the FDA received 1,503 adverse event reports associated with mesh used for POP repair, 5 times as many as the agency received from 2005 to 2007, according to the release.

In the mean time, lawsuits have piled up against multiple mesh makers, and patient advocacy groups have called for a mandated recall after an internal FDA research group recommended that additional clinical testing be required for new transvaginal mesh products.

The FDA isn’t likely to enforce a recall, Maisel told Bloomberg.

"There’s strong support in the clinical community that mesh serves a role for certain patients," Maisel said. "Our goal is not to completely remove these products from the market."

Wall Street didn’t seem to pay much notice, with share prices for JNJ, BCR and fellow mesh-maker Boston Scientific (NYSE:BSX) each losing less than 1% in value since the watchdog agency released its mandate yesterday.

Representatives for Johnson & Johnson subsidiary Ethicon Endosurgery and C.R. Bard did not return requests for comment.

Filed Under: Food & Drug Administration (FDA), Gynecological, Implants, News Well, Women's Health Tagged With: Boston Scientific, C.R. Bard, Endo Health, Ethicon, Johnson and Johnson

In case you missed it

  • House committee investigates $70M federal contract for AutoMedx ventilators
  • Edwards Lifesciences misses on earnings in Q4
  • COVID-19 assays sales power Hologic to Street-beating Q1
  • Stryker beats the Street on earnings but misses on revenue in Q4
  • How CGMs can inspire lifestyle changes
  • Johnson & Johnson gearing up for COVID-19 vaccine data announcement
  • Sanofi to provide COVID-19 vaccine manufacturing for rival Pfizer
  • Adapting to Pharma’s Next Normal – 2021 Pharmaceutical Trends
  • COVID-19 test sales boost Abbott in Street-beating Q4
  • Varian posts mixed bag Q1 results, expects Siemens Healthineers takeover to complete in early 2021
  • BD touts study of antigen test over molecular test for identifying infectious COVID-19 cases
  • Titan Medical closes on $11.5M offering
  • GE ticks up on mixed-bag Q4
  • BD CEO Polen to also serve as board chair
  • Moderna details ‘proactive’ strategy to fight emerging COVID-19 variants  
  • Surmodics’ DCB shown non-inferior to Medtronic’s In.Pact Admiral
  • Longeviti Neuro Solutions ClearFit implant wins FDA clearance for use in ultrasound

RSS From Medical Design & Outsourcing

  • House committee investigates $70M federal contract for AutoMedx ventilators
    A Congressional committee has launched an investigation into a $70 million White House contract for ventilators that reportedly are inadequate to treat people with COVID-19. The Department of Defense signed a $16.2 million contract in spring 2020 to buy SAVe II ventilators, manufactured by AutoMedx (Addison, Tex.), from the supplier Combat Medical Systems, according to… […]
  • How CGMs can inspire lifestyle changes
    As an early adopter of fitness trackers such as the Fitbit, I’ve long appreciated the power of health data. But my recent experience with a continuous glucose monitor (CGM) has done far more to inspire me to look after my health — even as a nondiabetic. I had heard about the potential of such technology… […]
  • COVID-19 mask factory opens in N.J.
    Hudson Holdings Group today announced it has opened a factory to make up to tens of millions of protective masks a month. The Piscataway, N.J., site will produce more than 200 jobs, according to the company, which is in partnership on the project with the State of New Jersey. “Our ultimate goal is to help,”… […]
  • TE Connectivity posts Street-beating Q1 results, medical sales dip 12%
    TE Connectivity (NYSE:TEL) posted first-quarter results today that beat the consensus on Wall Street. The Schaffhausen, Switzerland-based company reported profits of $381 million, or $1.13 per share, on sales of $3.5 billion for the three months ended Dec. 31, 2020, for a bottom-line gain of 1365.4% sales growth of 11.2% compared with Q1 2020. Adjusted to… […]
  • Could this 3-D printed ‘biomesh’ minimize hernia repair complications?
    Some hernia mesh implants have been associated with adverse post-surgical complications. So researchers at Baylor College of Medicine have developed a 3D-printed biomesh to support and reinforce the damaged abdominal wall and facilitate the healing process. Mesh implants may fail because they promote the adhesion of the intestine, liver or other visceral organs to the… […]
  • Superior Sensor Technology launches versatile differential pressure sensors
    Superior Sensor Technology (Santa Clara, Calif.) today announced the launch of differential pressure sensors for industrial applications that support up to seven selectable pressure ranges in one device. Designed for a wide range of applications, the new ND Series sensors support pressure ranges as low as 62.5 Pa/0.25” H2O to as high as 345 mBar/5… […]
  • BD touts study of antigen test over molecular test for identifying infectious COVID-19 cases
    Becton Dickinson (BD) is touting the results of a small, in-house study of its Veritor Plus antigen test over molecular (PCR) tests to indicate whether an infected person is more likely able to spread SARS-CoV-2. The peer-reviewed study compared antigen and PCR test results to positive results using a viral cell culture test. Viral growth… […]
  • TDK adds pressure sensors for ventilators
    TDK Corporation announced the launch of a new range of differential pressure sensors designed as printed circuit boards for use in medical devices. The sensors are designed for measurement ranges of 16 mbar full-scale (FS), 100 mbar FS and 7 bar FS, with accuracy of up to ±1% FS at temperatures from -20 °C to… […]
  • Pediatric device workshop scheduled for February
    A virtual public meeting on pediatric medical device development is scheduled for Feb. 9-11, 2021. Sponsors include the FDA, AdvaMed, the American Academy of Pediatrics and the Critical Path Institute, a public-private partnership that receives FDA funding. The System of Hospitals for Innovation in Pediatrics – Medical Devices (SHIP-MD) Virtual Workshop will focus on the… […]
  • Pedra wins breakthrough nod for perfusion system
    Singapore-based Pedra Technology announced today that the FDA has granted the company breakthrough device designation for the periprocedural use of its Xauron perfusion system in the treatment of critical limb-threatening ischemia (CLTI). CLTI is a severe form of peripheral artery disease (PAD) that is defined as ischemic rest pain, tissue loss or gangrene (tissue death) that… […]
  • Freudenberg Medical expands U.S. molding operations
    Freudenberg Medical announced that it has expanded injection molding operations at its Baldwin Park, Calif., operation, which is focused on thermoplastics. Freudenberg Medical Baldwin Park has added six injection molding machines including three new Arburg molding machines, a work cell for two-shot molding and a Wittmann Battenfeld micro-molding machine with in-process visual inspection capability. The… […]

Leave a Reply Cancel reply

You must be logged in to post a comment.

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS